2024-08-07 06:40:00 ET
One of the biggest narratives in the pharmaceutical space right now is that of weight-loss treatments.
Glucagon-like peptide 1 (GLP-1) agonists such as Ozempic and Wegovy are making significant headway among diabetes and obesity care patients. Both turned out to be blockbuster drugs , and are made by Danish pharmaceutical powerhouse Novo Nordisk (NYSE: NVO) .
Investors have cheered Novo as the company continues dominating the fast-growing GLP-1 market. But with shares of Novo Nordisk surging 57% over the last 12 months, you may be wondering if the train has left the station.
For further details see:
Is It Too Late to Buy Novo Nordisk Stock After Its 57% Surge?